数据日期 2026-10-29 · 生成时间 2026-10-29 06:03
研究问题
Alzheimer’s disease (AD) is a progressive neurodegenerative disorder considered to be one of the most common causes of cognitive decline.
方法
In addition, because global redocking of KYT-36 did not reproduce the crystallographic pose, a local optimization starting from the experimental KYT-36 geometry was performed to assess compatibility of the prepared Kgp receptor with the crystallographic binding mode.；Interaction Guided Dual-Target Prio] Pose refinement included analysis of hydrogen bonds, hydrophobic contacts, π-stacking, π-cation interactions, salt bridges, and halogen bonds, as well as other PLIP-supported interactions through the protein–ligand interaction profiler [24].；These included predicted blood–brain barrier permeation, confirmation that it is not a P-glycoprotein substrate, a molecular weight of 357.41, a TPSA of 54.79 Å2, and, crucially, no PAINS or Brenk alerts.；The calculated energetic components included van der Waals, electrostatic, polar solvation, and nonpolar solvation terms.
核心结论
Protein–ligand heteroatom distances of ≤3.5 Å were observed in 8.6% of analyzed frames, while distances of ≤4.0 Å occurred in 57.0% of frames, indicating intermittent polar proximity rather than a sustained hydrogen-bond interaction. ‖ 结论：Therefore, Kgp should only be considered as an investigative target rather than a clinically validated AD target.
局限
These observations are preliminary because independent MD replicates were not performed.
对本项目的价值
★★☆☆☆ 脑老化是最大未满足需求，也是终点最难量化的领域；biomarker 与认知读数选择最敏感。
全文来源
PMC JATS 全文（正文 36,734 字符，已过标题/DOI 逐字归属校验）
原文题录
- 英文标题：Targeting Cholinergic Dysfunction and Gingipain Activity in Alzheimer's Disease: A Dual AChE-Kgp Computational Study.
- 期刊与标识：Pharmaceuticals (Basel) · PMID 42943286 · DOI 10.3390/ph19101589**
B 级证据分级：B 级（同行评议临床前研究，主要为动物模型）
本文核心结论来自动物模型或体外细胞学，属临床前证据，不能外推至人体。「延长健康寿命」「改善功能」等表述在小鼠中的意义，与人类临床结局之间仍有距离。
关于本文的文献来源：本站依据 IMA 知识库「五刊监控·深度文献卡片」撰写，依据已获取的期刊全文（方法、样本量与结论已回到原文核对）；未能获取全文的同批条目另行标注「摘要级」，全程未做任何数值推算补全。